Tobradex (Tobramycin/Dexamethasone) Patent Expiration, LOE Window & CMS Spending
Tobradex (Tobramycin/Dexamethasone) by Sandoz: Off-Patent Genericized (AB Competition), 2 AB generics, $21.1M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Sandoz |
| FDA Application & Pathway | N050592 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $21.1M |
| 2024 Medicare Part D Spend | $15.5M |
| 2024 Medicaid Spend | $5.6M |
| Reported Wholesale Price Change (CA SB 17) | 3 WAC filings (max 24.4% 2-yr change) |